Hyperuricaemia - febuxostat (TA164)
Fast, easy summary view of NICE guidance on 'musculoskeletal conditions'
Febuxostat is recommended as a possible treatment for chronic hyperuricaemia in people with gout only if:
- they can't take the medicine allopurinol for medical reasons or
- the side effects of allopurinol are so bad that the person either has to stop taking it or can't be given the most effective dose.
People who were already taking febuxostat when the guidance was issued should be able to carry on taking it until they and their healthcare professional(s) decide that it is the right time to stop treatment.
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: musculoskeletal conditions
This page was last updated: 07 February 2014
Information for the public
Implementation tools and resources
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.